Table 7.
Endothelial Cell Type | ISOC: Electrophysiological and Pharmacological Features | Agonist Used to Reduce the [Ca2+]ER | Intracellular Ca2+ Buffering | Reference |
---|---|---|---|---|
BAECs | IR, Erev ≈ +6 mV, permeable to Na+, Ca2+ and Ba2+, PCa/PNa > 10, single-channel conductance: 5 pS (symmetrical Na2SO4), inhibited by 200 µM La3+ | tBHQ | 2 mM CaCl2, 5 mM BAPTA | [44,189] |
rPAECs | Slight IR, Erev ≈ +30/+40 mV, anomalous mole fraction behaviour, inhibited by 50 µM La3+ | Extracellular application of thapsigargin | [Ca2+]i buffered at 100 nm/L | [51,69,86,140,220,221] |
MAECs | IR, Erev ≈ +40 mV, Na+ permeability anomalous mole fraction behaviour, PCa/PNa ≈ 160, inhibited by 1 µM La3+ | Intracellular dialysis of InsP3 and extracellular application of tBHQ | 12 mM BAPTA | [87] |
EA.hy926 | IR, Erev ≈ −7 mV, anomalous mole fraction behaviour, Ca2+-dependent inactivation, inhibited by 10 µM La3+ | Extracellular application of thapsigargin | No CaCl2, no BAPTA/EGTA | [46] |
Abbreviations: BAECs: bovine aortic endothelial cells; IR: inward rectification; MAECs: mouse aortic endothelial cells; PCa/PNa: Ca2+/Na+ permeability ratio; rPAECs: rat pulmonary artery endothelial cells.